文章基本信息

标题：Natalizumab (Tysabri) in multiple sclerosis patients
本地全文：下载
作者：Viola Sacchi
期刊名称：Farmeconomia. Health economics and therapeutic pathways
印刷版ISSN：2240-256X
出版年度：2008
卷号：9
期号：2
页码：109-114
DOI：10.7175/fe.v9i2.222
语种：English
出版社：SEEd
摘要：Multiple sclerosis (MS) is an autoimmune disease where dysregulated immune system elements (i.e. leucocytes) react against different components of the central nervous system (CNS), in particular myelin structures, causing several physical and mental symptoms, often progressing to total disability. While some treatments for MS provide only symptom relief, the most commonly drugs administered for altering the course of the disease are DMTs (disease-modifying therapies); nevertheless for more than ten years the only DMTs available were interferon β, glatiramer acetate (two immunomodulating drugs) and mitoxantrone (an immunosuppressant).
关键词：Pharmacoeconomics; Health economics